Применение левофлоксацина в пульмонологии

1. Tilloston G.S., Blondeau J.M. Today’s community respiratory tra c t infections: a challenge appropriate for moxifloxacin. In: Adam D., Finch R., eds. Moxifloxacin in practice. Oxford: Maxim Medical; 1999; Voll: 1 — 11.

2. Яковлев С.В. Сравнительная оценка беталактамов и макролидов при внебольничных респираторных инфекциях. Антибиотики и химиотер. 2001; 46 (3): 1—4.

3. Sahm D. Pre-clinical microbiology — respiratory tra c t infections susceptibility survey — USA. In: Mandell L., ed. First International moxifloxacin symposium. Berlin: Springer Verlag; 2000; 54—58.

4. Schmitz F.J., Verhoe[ J., Fluit A.C. Comparative activities of 27 antimicrobial compounds against 698 Streptococcus pneumoniae isolates. In: J.Antimicrob. Chemother.1999; 44 (suppl. A): Abstr. N P 199.

5. Tavanic (levofloxacin) IV /o ra l. Scientific Product Monograph. - Hoechst Marion Roussel.

6. Barry A.L., Fuchs P.C., Allen S.D. In vitro susceptibilityu of Streptococcus pneumoniae to the d- and 1-isomers of ofloxacin: interpretive criteria and quality control limits. J.Antimicrob. Chemother. 1996; 37: 365—369.

7. Yamane Y., Jones R.N., Frei R. et al. Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. J.Chemother. 1994; 6: 83—91.

8. Baltch A.L., Smith R.P., Ritz W. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampicin used singly and in combination against Legionella pneumophila. Antimicrob. Agents. Chemother. 1995; 39: 1661—1666.

9. Molitoris E., Wexler H.M., Finegold S.M. In vitro activity of levofloxacin against bacteria from skin and soft tissue infections. In: 36th Intersciences conferense on antimicrobial agents chemotherapy. New Orleans; 1996. Abstr. N E88.

10. Goldstein E.J.C., Nesbit C.A., Citron DM. Comparative in vitro activities of azithromycin, Bay у 3118, levofloxacin, sparfloxacin, and 11 other oral anti-microbial agents against 194 aerobic and anaerobic bite wound isolates. Antimicrob. Agents Chemother. 1995; 39: 1097—1100.

11. Child J., Mortiboy D., Andrews J.M. et al. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluids. Ibid. 2749—2751.

12. Lee L.J., Sha X., Gotjried M. et al. Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy. Pharmacotherapy 1998; 180: 35—41.

13. Gaja М., Higa F., Yamashiro T. et al. Penetration of levofloxacin, a new quinolone antibacterial agent, inti to human neutrophils. Chemotherapy (Tokyo) 1992; 40 (suppl.3): 64—67.

14. Taira K., Toga H., Kohno S. Accumulastion of a newly developed fluoroquinolone, OPC-17116, bay human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 1993; 37: 1877—1881.

15. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. N. Engl. J. Med. 1995; 333: 1618—1624.

16. Fass R.J. Aetiology and tre a tm en t of community-acquired pneumonia in adults: an historical perspective. J. Antimicrob. Chemother. 1993; 32 (suppl. A): 17—27.

17. Marrie T.J. Community-acquired pneumonia. Clin. Infects. Dis. 1994; 18: 501—513.

18. Marrie T.J., Peeling R.W., Fine M.J. et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical ag ents and clinical course. Am.J. Med. 1996; 101: 508—515.

19. Fogarty C.M., Sullivan J.G., Chattman M.S. et al. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults. Infect.Dis.Clin.Pract. 1998; 7: 400—407.

20. Kahn J.B., Wiesenger B.A., Williams R.R. Levofloxacin in the treatment of community-acquired pneumonia due to penicillin- and macrolide-resistant pneumococci. In: 39th Intersciences conference antimicrobial agents chemotherapy. San Francisco; 1999. 12.

21. Wiesenger B.A., Kahn J.B., Morgan N. Efficacy of levofloxacin in the treatment of community-acquired pneumonia due to macrolide resistant Streptococcus pneumoniae. In: 5th International conference macrolides, azalides, streptogramins, ketolides and oxazolidinones. Seville; 2000. Abstr. N 423.

22. File T.M. Levofloxacin in the trea tm en t of community-acquired pneumonia. Clin. Respir. J. 1999; 6 (suppl. A): 35A—39A.

23. Kahn J.B., Wiesenger B.A., Oross M.P. et al. Levofloxacin versus azithromycin plus ceftriaxone in moderate to severe communityacquired pneumonia (CAP). In: 5th International conference on macrolides, azalides, streptogramins, ketolides and oxazolidinones. Seville; 2000. Abstr. N 424.

24. Carbon C., Ariza H., Rabie W.J. et al. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mildto-moderate community-acquired pneumonia. Clin. Microbiol. Infect. 1999; 5: 724—732.

25. Gottfried M., Sullivan J.G., Mayer H. et al. A randomised, double-blind, multicenter, comparative study of gatifloxacin (GAT) vs levofloxacin (LEV) in treatment of community-acquired pneumonia (CAP). In: 39th Intersciences conference antimicrobial agents chemotherapy. San Francisco; 1999. Abstr. N 2243.

26. Williams R.R., Fogarty C., Dunbar L. et al. The efficacy of levofloxacin in the treatment of community-acquired pneumonia due to Mycoplasma pneumoniae or Chlamydia pneumoniae. Clin. Infect. Dis. 1998; 27: Abstr. N 168.

27. Hammerschlag M.R., Robbin P.M. Microbiology efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob. Agents Chemother. 2000; 44 (5): 1409.

28. Williams R.R., Stout J.E., Yu R.N. et al. Levofloxacin is safe and effective in the management of community-acquired pneumonia (CAP) due to Legionella. In: 6th International symposium on new quinolones. Denver; 1998. Abstr. N 96.

29. Hammerschlag M.R., Reznik T.t Robin P. Microbiology efficacy of levofloxacin for the treatment of serious community-acquired pneumonia due to Chlamydia pneumoniae. J.Antimicrob. Chemother. 2001; 41 (suppl. SI ) : Abstr. P 112.

30. Kahn J.B., Wiesenger A., Olson W.H. et al. Levofloxacin vs. ceftriaxone sodium and erythromycin in th trea tm en t of patients with community-acquired pneumonia (CAP) at high risk of mortality. Ibid. Abstr. N P 115.

31. O’Hare M., Harding I. Levofloxacin therapy for community-acquired pneumonia due to atypical and intracellular microorganisms. Abstr. N P 119.

32. Harding I., O’Hare M. Levofloxacin for the trea tm en t of community-acquired pneumonia: clinical advantages over other empiric therapies. Ibid. Abstr. N P 121.

33. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest l995 ; 108 (supp l.1): 4 3S—52S.

34. Anthonisen N.R., Manfreda J., Warren C.P.W. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196—204.

35. Burley C.J., Masterton R.G. A double-blind comparison of oral levofloxacin 500 mg once daily for 7 days in patients with acute exacerbation of chronic bronchitis. Clin. Microbiol. Infect. 1999; 5 (suppl.3): 276, Abstr. N P 715.

36. Shah P.M., Maesen F.P. V., DolmannA. et al. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomised, double-blind study. J.Antimicrob. Chemother. 1999; 43: 529—539.

37. Davies B.I., Maesen F.P.V. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. Ibid. (suppl. C): 83—90.